Dimension Therapeutics expands internal R&D
Dimension Therapeutics, a gene therapy company advancing novel, liver-directed treatments for diverse rare diseases, plans to expand the company’s internal research and process development capabilities. Dimension has signed a lease agreement with Alexandria Real Estate Equities, for 17,475 square feet of state-of-the-art laboratory and office space at 19 Presidential Way in Woburn, Mass., with occupancy expected in April 2016. The expansion builds upon Dimension’s existing mammalian cell platform in Cambridge, and will support continued innovation in vector optimization and development of manufacturing processes required for IND-enabling studies and the reliable production of high-quality AAV vectors at commercial scale.
“Dimension’s current pipeline has grown substantially over the past 12 months, and the new facility will allow us to meet our needs, as well as accommodate additional, anticipated growth in the portfolio. This includes our entry into clinical testing with our lead candidate, DTX101 for hemophilia B, by the end of this year and further advancement of our therapeutic pipeline in hemophilia A and other rare, monogenic diseases associated with the liver,” said Dimension CEO Annalisa Jenkins, MBBS, MRCP. “Since its founding, Dimension has made the Greater Boston and Cambridge area its home. We consider ourselves fortunate to be in one of the world’s leading centers for the life sciences, attracting top-tier talent with close proximity to leading researchers, academic institutions, medical facilities and a vibrant business community.”
Founded in 2013, Dimension maintains headquarters in Cambridge, Mass.